Etude de la qualité de vie et de l’impact médico-économique de la maladie de Willebrand en France (WiSH-QoL)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/107761
• EU PAS number:
  EUPAS107760
• Study ID:
  107761
• Official title and acronym:
  Etude de la qualité de vie et de l’impact médico-économique de la maladie de Willebrand en France (WiSH-QoL)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  This was an observational, non-interventional, descriptive study, without modification of the doctor-patient relationship, conducted across 28 French specialized VWD centers. Patient's recruitment concerns male and female of any age with congenital Von Willebrand Disease (VWD). Quality of life analysis is based on generic and Von Willebrand Disease-specific quality of life questionnaires.
• Study status:
  Finalised

Research institutions and networks

Networks

Centre de Référence de la Maladie de Willebrand (CRMW)

Study timelines

Date when funding contract was signed

Actual: 09/08/2014

Study start date

Actual: 01/10/2014

Data analysis start date

Actual: 31/03/2022

Date of interim report, if expected

Actual: 25/05/2018

Date of final study report

Actual: 30/11/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

LFB BIOMEDICAMENTS

Study protocol

Initial protocol

Synopsis WiSH-QoL v3.0 - 23 10 2020_VEnglish final

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable